Looking to publish in Human Vaccines & Immunotherapeutics? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowHuman Vaccines & Immunotherapeutics is an international open access peer-reviewed journal focused on human vaccinology and immunotherapy. It publishes research on novel vaccines and immunotherapeutics, preclinical studies, clinical trials, disease mechanisms, licensed products, vaccine acceptance and hesitancy, policy, safety, surveillance, epidemiology, pharmaco-economics, and related public health topics. The journal operates single-anonymized peer review, is affiliated with the International Society for Vaccines and the Association for Cancer Immunotherapy, and has been fully open access since Volume 18 in 2022.
Looking to publish in Human Vaccines & Immunotherapeutics? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.
Try Livewrite NowSubmission Instructions
Human Vaccines & Immunotherapeutics accepts the following article types. Click on an article type to view submission instructions.
Research Articles
Review Article
State-Of-The-Art Reviews
Case Report
Rapid Communication
Mini-Reviews
Recent Publications
Acceptance of the respiratory syncytial virus infant monoclonal antibody nirsevimab among post-partum women in Italy
Silvia Angelillo, Grazia Miraglia del Giudice, Giorgia Della Polla, Italo Francesco Angelillo, Carlo Capristo, Francesco Tarsitano, Ilias Urciuoli, Emilia Anna Vozzella
Safety and immunogenicity of a booster dose of COVAC-2, a Sepivac SWE™ adjuvanted SARS-CoV-2 recombinant protein vaccine in previously vaccinated healthy adults; a randomized controlled multicentre trial
Glenn Hamonic, Supriya Arora, Ravendra Garg, Erin Scruten, Rachelle Buchanan, Stephanie L. Saundh, Nicolas Collin, Stephen Sanche, Noah Vale, Timothy Salter, Scott A. Halperin, Joanne M. Langley, Volker Gerdts, Trina Racine
Current practices, opportunities to improve, and behavioral targets related to HPV vaccination in community pharmacies: A qualitative study of pharmacy staff and parents
Jessie Schwartz, Katherine Meehan, Eliza B. Cohn, Jennifer L. Bacci, William A. Calo, Linda K. Ko, Parth D. Shah
A cross-sectional survey of general practitioners’ influenza vaccination willingness and influencing factors based on the reasoned action approach
Yundi Ma, Yangni Li, Mingmin Chen, Jingjing Ren, Linlin Xu
Safety and immunogenicity of 4CMenB and MenACWY-CRM meningococcal vaccines when administered concomitantly in healthy adolescents: A phase 3b, randomized, observer-blind study
Alejandro Hoberman, Jibran Atwi, Peter Silas, Rosa Prato, Samantha Bosis, Judith M. Martin, Isabelle Lechevin, Mariapia Possidente, Sara Manzella, Luca Moraschini, Maria Lattanzi, Pavitra Keshavan
Frequently asked questions
How long does it take to publish?
25 days average from submission to first decision; 48 days average from submission to first post-review decision; 14 days average from acceptance to online publication.
Reformat to Human Vaccines & Immunotherapeutics using Livewrite PremiumIs a cover letter required?
A cover letter is not used for APC waiver requests. Waiver requests must be made at the time of online submission, not in a cover letter.
Reformat to Human Vaccines & Immunotherapeutics using Livewrite PremiumWhat are the publication costs?
Open access costs may be covered by a Taylor & Francis open access agreement; journal-specific charges vary.
Reformat to Human Vaccines & Immunotherapeutics using Livewrite Premium